

2010 PQRI Measures Groups

Measure Number	Measure Title
Diabetes Mellitus Measures Group	
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients
163	Diabetes Mellitus: Foot Exam
Chronic Kidney Disease (CKD) Measures Group	
121	Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile)
122	Chronic Kidney Disease (CKD): Blood Pressure Management
123	Chronic Kidney Disease (CKD): Plan of Care - Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA)
135	Chronic Kidney Disease (CKD): Influenza Immunization
153	Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula
Preventive Care Measures Group	
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
110	Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 years and Older
112	Preventive Care and Screening: Screening Mammography
113	Preventive Care and Screening: Colorectal Cancer Screening
114	Preventive Care and Screening: Inquiry Regarding Tobacco Use
115	Preventive Care and Screening: Advising Smokers and Tobacco Users to Quit
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
173	Preventive Care and Screening: Unhealthy Alcohol Use – Screening

2010 PQRI Measures Groups

Coronary Artery Bypass Graft (CABG) Measures Group	
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation (Ventilation)
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate
166	Coronary Artery Bypass Graft (CABG): Stroke/Cerebrovascular Accident (CVA)
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Insufficiency
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge
171	Coronary Artery Bypass Graft (CABG): Lipid Management and Counseling
Rheumatoid Arthritis Measures Group	
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
176	Rheumatoid Arthritis (RA): Tuberculosis Screening
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity
178	Rheumatoid Arthritis (RA): Functional Status Assessment
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis
180	Rheumatoid Arthritis (RA): Glucocorticoid Management
Perioperative Care Measures Group	
20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician
21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
Back Pain Measures Group	
148	Back Pain: Initial Visit
149	Back Pain: Physical Exam
150	Back Pain: Advice for Normal Activities
151	Back Pain: Advice Against Bed Rest

2010 PQRI Measures Groups

Hepatitis C Measures Group	
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment
85	Hepatitis C: HCV Genotype Testing Prior to Treatment
86	Hepatitis C: Antiviral Treatment Prescribed
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV
Heart Failure (HF) Measures Group	
5	Dysfunction (LVSD)
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
114	Inquiry Regarding Tobacco Use (Preventive Care and Screening)
115	Advising Smokers and Tobacco Users to Quit (Preventive Care and Screening)
198	Heart Failure: Left Ventricular Function (LVF) Assessment
199	Heart Failure: Patient Education
Coronary Artery Disease (CAD) Measures Group	
6	Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
114	Inquiry Regarding Tobacco Use (Preventive Care and Screening)
115	Advising Smokers and Tobacco Users to Quit (Preventive Care and Screening)
196	Coronary Artery Disease (CAD): Symptom and Activity Assessment
197	Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol
Ischemic Vascular Disease (IVD) Measures Group	
114	Inquiry Regarding Tobacco Use (Preventive Care and Screening)
115	Advising Smokers and Tobacco Users to Quit (Preventive Care and Screening)
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control
202	Ischemic Vascular Disease (IVD): Complete Lipid Profile
203	Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic

2010 PQRI Measures Groups

HIV/AIDS Measures Group	
159	HIV/AIDS: CD4 + Cell Count or CD4 + Percentage
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea
206	HIV/AIDS: Screening for High Risk Sexual Behaviors
207	HIV/AIDS: Screening for Injection Drug Use
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis
Community-Acquired Pneumonia (CAP) Measures Group	
56	Community-Acquired Pneumonia (CAP): Vital Signs
57	Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation
58	Community-Acquired Pneumonia (CAP): Assessment of Mental Status
59	Community-Acquired Pneumonia (CAP): Empiric Antibiotic